Medicus Pharma Ltd. (MDCX) has officially submitted an application to the U.S. Food and Drug Administration (FDA) seeking orphan drug designation for its innovative drug Skinject®, with the indication for Gorlin Syndrome (Basal Cell Nevus Syndrome).
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Will a 10-year US Treasury yield rising to 5.5% "attack" US stocks? Societe Generale warns: this could be the valuation tipping point.
Bokobza, Global Head of Asset Allocation at Société Générale, pointed out that if the 10-year U.S. Treasury yield reaches 5.5%, corporate profit growth will not be sufficient to offset the impact of rising rates on valuations, and the stock market will face substantial pressure. However, he believes that the upcoming rate hikes by the Federal Reserve and the European Central Bank will be relatively limited and will not disrupt the current economic cycle.
The Dream of Big Profits in These Altcoins Didn’t Come True: Only 229 Users Managed to Earn $10,000! Here Are the Details
XRP Stuck in Range as $1.50 Breakout Level Comes Into Focus
Cilo Cybin publishes integrated annual report for year ended March 31, 2026
Crypto prices
More
